Kolmar BioTech
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Woojung BIO provides laboratory testing services used to assess the safety and quality of pharmaceuticals, medical devices, and related products, including tests that check for genetic toxicity, bacterial contamination, and sterilisation effectiveness.
Its clients are broadly companies and researchers in the life-sciences and pharmaceutical industries that need independent, regulated testing before products can be approved. The company is listed on KOSDAQ, South Korea's technology and small-cap stock exchange. Its service portfolio spans both cell-based (in-vitro) and live-organism (in-vivo) testing methods, as well as specialised techniques such as surface plasmon resonance screening used in early-stage drug discovery.
Summary is AI-generated and may contain errors · figures from DART filings
Kolmar BioTech in five facts
What does Kolmar BioTech do?
Woojung BIO provides laboratory testing services used to assess the safety and quality of pharmaceuticals, medical devices, and related products, including tests that check for genetic toxicity, bacterial contamination, and sterilisation effectiveness.
Where is Kolmar BioTech listed and in which sector?
Kolmar BioTech (Korean name: 콜마바이오텍) trades under KRX code 215380 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Biotechnology.
How large is Kolmar BioTech?
Its market capitalisation was US$26.9M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Kolmar BioTech's latest annual revenue and operating profit?
For fiscal year 2025, Kolmar BioTech reported revenue of US$28.4M, an operating loss of US$2.9M and a net loss of US$4.2M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 13.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Completion report on merger, etc. (merger)M&A · Sep 22
- Conversion price adjustmentAug 31
- [Amended] Material event report (merger)
Kolmar BioTech Co., Ltd. (listed under the "Woojung BIO" name in this filing's header, as stated in the filing, though the filing body identifies the filer as Kolmar BioTech Co., Ltd.) amended its July 20, 2026 merger report to attach the final merger agreement in place of the draft, for a small-scale merger in which Kolmar BioTech absorbs its wholly owned subsidiary MOD Materials Co., Ltd. (2025 total assets US$2.49M, total liabilities US$2.04M, revenue US$10.5M) without issuing new shares, at a merger ratio of 1:0, with a scheduled merger effective date of September 22, 2026.
M&A · Jul 21 · 2 versions - [Amended] Material event report (convertible bonds)
Kolmar BioTech updated the terms of convertible bonds to raise US$23.1M, about 91.4% of its market value.
Capital raise · Mar 30 · 2 versions - Agreement on change of control signedOwnership change · Mar 27
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Kolmar BioTech reported separate results for FY2025: revenue of US$26M (−13% year on year), an operating loss of US$2.77M (from a profit a year earlier) and a net loss of US$3.89M (from a profit a year earlier).
Earnings · Feb 12